| HOME >> MEDICINE >> TECHNOLOGY |
$
31,362Adjustment related to Novartis collaboration and other, net
13,275
(1)Non-GAAP adjusted revenues
$
44,637EARNINGS PER SHAREGAAP earnings per share- Diluted
$
.01$
.08Adjustments to net income (as detailed below)
0.370.26Non-GAAP adjusted earnings per share- Diluted
$
.38
(2)$
.34
(2)NET INCOMEGAAP net income
$
3,118$
20,812Adjustments:Contingent revenue from Novartis collaboration
and other, net
13,275-Amortization of intangible assets103,813
(3)61,013
(3)Contingent consideration
39,526
(4)15,563
(4)Non-cash interest expense relating to convertible notes
15,644
(5)18,953
(5)Acquisition-related costs
5,521
(6)1,084
(6)Restructuring
3,933
(7)(91)
(7)Fair value write up of acquired inventory sold
29,876
(8)-Fair value adjustment for depreciation expense
2,689
(9)-Gain on sale of intellectual property, net
(53,884)
(10)-Other gains
(3,367)
(11)-Income tax effect of reconciling items
(58,366)
(12)(27,293)
(13)Non-GAAP adjusted net income
$
,778$
90,041EBITDANon-GAAP adjusted net income
$
,778$
90,041Interest expense, net, not adjusted above
56,1779,723Provision for income taxes
47,89546,385Depreciation expense, not adjusted above
21,65316,110Adjusted EBITDA
$
227,503$
2,259Explanatory Notes:(1) To primarily reflect a fair value adjustment recorded in purchase accounting relating to contingent revenue earned and received under the Novartis
'/>"/>
| SOURCE Hologic, Inc. Copyright©2012 PR Newswire. All rights reserved |